A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients.

Trial Profile

A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Pramipexole (Primary) ; Ropinirole
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 14 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 09 Dec 2008 Status changed from recruiting to active, no longer recruiting, as reported on ClinicalTrials.gov.
    • 11 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top